The EVERSENSE PASSTM program can help make the EVERSENSE® E3 Continuous Glucose Monitoring System more affordable for you – now and in the future!
The Program Provides Support For Patients' First Year — And Beyond
$99* FOR YOUR FIRST SENSOR/TRANSMITTER, AND SECOND SENSOR
Available the first full year. Eligible patients can experience EVERSENSE E3 CGM for only $99 for initial sensor and transmitter, and $99 for the second sensor.
$600 MAX OUT-OF-POCKET FOR FUTURE SENSORS/TRANSMITTERS
After the first full year on Eversense E3, out-of-pocket expenses are not to exceed $600 for the patient’s next sensor or sensor/transmitter combination and may be less depending on the patient’s insurance plan.
Offers do not apply to the insertion and removal procedures.
How Patients Can Redeem These Offers:
The Eversense PASS Program will be applied to eligible patients who purchase Eversense E3 CGM directly through a participating Strategic Fulfillment Partner. Patients will be informed of eligibility by the Strategic Fulfillment Partner when discussing out-of-pocket costs.
If purchasing through a Non-Participating Strategic Fulfillment Partner, the patient will need to complete and submit the form on reverse side with supporting documentation. The patient will be notified by their Strategic Fulfillment Partner or Ascensia Diabetes Therapy Associate on the appropriate steps for enrollment.
‡The offers above only apply to the cost of the sensor and transmitter or sensor only. They do not cover the cost of the insertion procedure. Limitations and Restrictions may apply. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which patient out-of-pocket costs exceed what is detailed in INTRO and ONGOING offers.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia and the Ascensia Diabetes Care logo are trade marks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. Android is a trademark of Google LLC. Apple Watch is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
See below for terms and conditions. Certain restructions apply. Please complete the appropriate sections(s) of the form and check all boxes to confirm your agreement with the terms and conditions, patient authorization and patient attestations.
* indicates required field.
Ascensia Diabetes Care 5 Wood Hollow Road Parsippany NJ 07054 United States 1-800-348-8100 (CONTOUR Blood Glucose Monitoring) 1-844-736-7348 (Eversense Continuous Glucose Monitoring)